Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC decreased its position in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 10.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,720 shares of the biotechnology company’s stock after selling 1,300 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Anika Therapeutics were worth $265,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC increased its position in shares of Anika Therapeutics by 7.8% in the 1st quarter. SG Americas Securities LLC now owns 8,615 shares of the biotechnology company’s stock valued at $219,000 after purchasing an additional 627 shares during the last quarter. Eastern Bank purchased a new position in Anika Therapeutics in the third quarter valued at $28,000. Massachusetts Financial Services Co. MA raised its stake in Anika Therapeutics by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 47,691 shares of the biotechnology company’s stock valued at $1,208,000 after buying an additional 1,601 shares in the last quarter. American Century Companies Inc. lifted its holdings in Anika Therapeutics by 11.8% during the 2nd quarter. American Century Companies Inc. now owns 23,892 shares of the biotechnology company’s stock worth $605,000 after buying an additional 2,518 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Anika Therapeutics by 16.9% during the 1st quarter. BNP Paribas Financial Markets now owns 22,240 shares of the biotechnology company’s stock worth $565,000 after acquiring an additional 3,217 shares in the last quarter. Institutional investors and hedge funds own 91.53% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ANIK. StockNews.com lowered Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 4th. Barrington Research reduced their price objective on shares of Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday, November 1st.

Anika Therapeutics Stock Performance

Shares of ANIK stock opened at $17.04 on Tuesday. Anika Therapeutics, Inc. has a 1 year low of $16.00 and a 1 year high of $29.11. The firm has a market cap of $249.64 million, a price-to-earnings ratio of -2.59 and a beta of 0.86. The stock’s 50-day moving average is $22.96 and its two-hundred day moving average is $25.02.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.